Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant humanized antibody expressed in CHO binding to human CD79B. Polatuzumab Vedotin is an anti-CD79b antibody-drug conjugate (ADC), and is composed of a monoclonal antibody (MAb), a stable linker, and the cytotoxic auristatin, and it is designed to selectively bind to CD79b while minimizing cytotoxic effects on hematologic cells that do not express CD79b.
Target
CD79B
Type
IgG1 - kappa
Immunogen
The details of the immunogen for this antibody are not available.
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, ICC and most other immunological methods.
CAS
1313206-42-6
Predicted N terminal
EVQLVESG
Molecular Weight
Approximately 150 kDa
Purity
>95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
Size
1mg
Storage
4°C. For long term storage, aliquot and store at -20°C. Repeated thawing and freezing must be avoided.
BACKGROUND
Introduction
Polatuzumab Vedotin is an anti-CD79b antibody-drug conjugate (ADC), and is composed of a monoclonal antibody (MAb), a stable linker, and the cytotoxic auristatin, and it is designed to selectively bind to CD79b while minimizing cytotoxic effects on hematologic cells that do not express CD79b.
Antigen Description
Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.